** Shares of drug developer Compass Pathways CMPS.O rise 12.4% to $6.69 premarket

** Co says it is moving up its commercial launch plans for its experimental depression treatment COMP360, by up to a year, following a positive meeting with the U.S. FDA

** CMPS's COMP360 is being developed for people with treatment-resistant depression

** Co now expects to release key data from its ongoing clinical trials in early 2026, as well as additional results from late-stage trials

** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says

** Up to last close, stock up ~57% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))